HISTORY
Half a Century of History:
| 2012 | Cetraxal plus is launched in Mexico as Infalin |
| 2011 | Cetraxal plus is launched in Italy as Cexidal |
| 2010 | Approval of Cetraxal Otic Solution in Europe through a descentralized procedure |
| 2009 | FDA approves Cetraxal Otico Solution, which is then marketed in the USA in collaboration with WraSer Pharmaceuticals |
| 2008 | Malacur is launched in Africa |
| 2007 | Blow-Fill-Seal technology is introduced at our production facility |
| 2006 | Approval letter for Cetraxal in USA and IND for Tarafenacin |
| 2005 | Launch of Levogastrol and Eberconazole (a new chemical entity with worldwide patent) |
| 2002 | Cetraxal Plus Ear Drops are launched (unique combination) |
| 2001 | Zayasel Solution launch |
| 2000 | Inauguration of the new R&D Centre |
| 1997 | Monolitum is launched |
| 1995 | Cetraxal Ear drops (a world first) are launched |
| 1989 | Cetraxal is launched |
| 1987 | Ulcetrax is launched with the “SALVAT original process patent” |
| 1986 | The OTC Division is created, and Cristalmina is launched |
| 1984 | SALVAT moves to its current headquarters |
| 1982 | SALVAT’s International Division is created |
| 1973 | INSALQUISA is established |
| 1972 | Vinciseptil Otico is launched |
| 1959 | SALVACOLINA is launched |
| 1955 | SALVAT Laboratory is established |
